Evaluation of the effect of Vacciniumarctostaphylos L. fruit extract on serum inflammatory biomarkers in adult hyperlipidemic patients: a randomized double-blind placebo-controlled clinical trial

Atherosclerosis is a chronic inflammatory condition. Many pro-inflammatory factors including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), and adhesion molecules including intercellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1) are exp...

Full description

Bibliographic Details
Main Authors: Sedigheh Asgary, Rasool Soltani, Saeide Mirvakili, Nizal Sarrafzadegan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Research in Pharmaceutical Sciences
Subjects:
Online Access:http://www.jrps.ir/article.asp?issn=1735-5362;year=2016;volume=11;issue=4;spage=343;epage=348;aulast=Asgary
id doaj-910bdd7e9a284fd1be28d9ca89748a0e
record_format Article
spelling doaj-910bdd7e9a284fd1be28d9ca89748a0e2021-08-02T19:53:17ZengWolters Kluwer Medknow PublicationsResearch in Pharmaceutical Sciences1735-53621735-94142016-01-0111434334810.4103/1735-5362.189321Evaluation of the effect of Vacciniumarctostaphylos L. fruit extract on serum inflammatory biomarkers in adult hyperlipidemic patients: a randomized double-blind placebo-controlled clinical trialSedigheh AsgaryRasool SoltaniSaeide MirvakiliNizal SarrafzadeganAtherosclerosis is a chronic inflammatory condition. Many pro-inflammatory factors including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), and adhesion molecules including intercellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1) are expressed in atherosclerotic lesions. The plants of genus Vaccinium are rich in anthocyanins with anti-inflammatory effects. This study aimed to evaluate the effects of Vaccinium arctostaphylos fruit extract on the serum level of TNF-α, IL-6, ICAM-1, and VCAM-1 in adult patients with mild hyperlipidemia to detect its possible inhibitory effects on progression of atherosclerosis. In a randomized double-blind placebo-controlled clinical trial, eligible hyperlipidemic patients were randomly and equally divided in to two groups of study drug or placebo control to receive either the Vaccinium extract or placebo capsules, respectively, twice daily for four consecutive weeks. Each drug capsule contained 0.8 mg of anthocyanins. Serum levels of TNF-α, IL-6, ICAM-1, and VCAM-1 were measured before and after the interventions and finally were compared.A total of 8 men and 12 women in drug group as well as 11 men and 9 women in placebo group completed the study (P = 0.527). The use of Vaccinium extract significantly reduced only the IL-6 level (P = 0.037); however, this reduction was not significant compared to placebo (P = 0.062). Consumption of Vaccinium arctostaphylos fruit extract with the dose of 500 mg twice daily did not show any significant effect on serum levels of TNF-α, IL-6, ICAM-1, and VCAM-1 in adult hyperlipidemic patients. However, considering slight decrease in the level of IL-6, ICAM-1, and VCAM-1, the use of higher doses with longer duration might have significant effects on these factors.http://www.jrps.ir/article.asp?issn=1735-5362;year=2016;volume=11;issue=4;spage=343;epage=348;aulast=AsgaryClinical trial; Hyperlipidemia; Inflammatory factors; Vaccinium arctostaphylos
collection DOAJ
language English
format Article
sources DOAJ
author Sedigheh Asgary
Rasool Soltani
Saeide Mirvakili
Nizal Sarrafzadegan
spellingShingle Sedigheh Asgary
Rasool Soltani
Saeide Mirvakili
Nizal Sarrafzadegan
Evaluation of the effect of Vacciniumarctostaphylos L. fruit extract on serum inflammatory biomarkers in adult hyperlipidemic patients: a randomized double-blind placebo-controlled clinical trial
Research in Pharmaceutical Sciences
Clinical trial; Hyperlipidemia; Inflammatory factors; Vaccinium arctostaphylos
author_facet Sedigheh Asgary
Rasool Soltani
Saeide Mirvakili
Nizal Sarrafzadegan
author_sort Sedigheh Asgary
title Evaluation of the effect of Vacciniumarctostaphylos L. fruit extract on serum inflammatory biomarkers in adult hyperlipidemic patients: a randomized double-blind placebo-controlled clinical trial
title_short Evaluation of the effect of Vacciniumarctostaphylos L. fruit extract on serum inflammatory biomarkers in adult hyperlipidemic patients: a randomized double-blind placebo-controlled clinical trial
title_full Evaluation of the effect of Vacciniumarctostaphylos L. fruit extract on serum inflammatory biomarkers in adult hyperlipidemic patients: a randomized double-blind placebo-controlled clinical trial
title_fullStr Evaluation of the effect of Vacciniumarctostaphylos L. fruit extract on serum inflammatory biomarkers in adult hyperlipidemic patients: a randomized double-blind placebo-controlled clinical trial
title_full_unstemmed Evaluation of the effect of Vacciniumarctostaphylos L. fruit extract on serum inflammatory biomarkers in adult hyperlipidemic patients: a randomized double-blind placebo-controlled clinical trial
title_sort evaluation of the effect of vacciniumarctostaphylos l. fruit extract on serum inflammatory biomarkers in adult hyperlipidemic patients: a randomized double-blind placebo-controlled clinical trial
publisher Wolters Kluwer Medknow Publications
series Research in Pharmaceutical Sciences
issn 1735-5362
1735-9414
publishDate 2016-01-01
description Atherosclerosis is a chronic inflammatory condition. Many pro-inflammatory factors including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), and adhesion molecules including intercellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule (VCAM-1) are expressed in atherosclerotic lesions. The plants of genus Vaccinium are rich in anthocyanins with anti-inflammatory effects. This study aimed to evaluate the effects of Vaccinium arctostaphylos fruit extract on the serum level of TNF-α, IL-6, ICAM-1, and VCAM-1 in adult patients with mild hyperlipidemia to detect its possible inhibitory effects on progression of atherosclerosis. In a randomized double-blind placebo-controlled clinical trial, eligible hyperlipidemic patients were randomly and equally divided in to two groups of study drug or placebo control to receive either the Vaccinium extract or placebo capsules, respectively, twice daily for four consecutive weeks. Each drug capsule contained 0.8 mg of anthocyanins. Serum levels of TNF-α, IL-6, ICAM-1, and VCAM-1 were measured before and after the interventions and finally were compared.A total of 8 men and 12 women in drug group as well as 11 men and 9 women in placebo group completed the study (P = 0.527). The use of Vaccinium extract significantly reduced only the IL-6 level (P = 0.037); however, this reduction was not significant compared to placebo (P = 0.062). Consumption of Vaccinium arctostaphylos fruit extract with the dose of 500 mg twice daily did not show any significant effect on serum levels of TNF-α, IL-6, ICAM-1, and VCAM-1 in adult hyperlipidemic patients. However, considering slight decrease in the level of IL-6, ICAM-1, and VCAM-1, the use of higher doses with longer duration might have significant effects on these factors.
topic Clinical trial; Hyperlipidemia; Inflammatory factors; Vaccinium arctostaphylos
url http://www.jrps.ir/article.asp?issn=1735-5362;year=2016;volume=11;issue=4;spage=343;epage=348;aulast=Asgary
work_keys_str_mv AT sedighehasgary evaluationoftheeffectofvacciniumarctostaphyloslfruitextractonseruminflammatorybiomarkersinadulthyperlipidemicpatientsarandomizeddoubleblindplacebocontrolledclinicaltrial
AT rasoolsoltani evaluationoftheeffectofvacciniumarctostaphyloslfruitextractonseruminflammatorybiomarkersinadulthyperlipidemicpatientsarandomizeddoubleblindplacebocontrolledclinicaltrial
AT saeidemirvakili evaluationoftheeffectofvacciniumarctostaphyloslfruitextractonseruminflammatorybiomarkersinadulthyperlipidemicpatientsarandomizeddoubleblindplacebocontrolledclinicaltrial
AT nizalsarrafzadegan evaluationoftheeffectofvacciniumarctostaphyloslfruitextractonseruminflammatorybiomarkersinadulthyperlipidemicpatientsarandomizeddoubleblindplacebocontrolledclinicaltrial
_version_ 1721227406506721280